Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study

Nagao, Shoji; Nishio, Shin; Takehara, Kazuhiro; Sato, Shinya; Satoh, Toyomi; Shimada, Muneaki; Yamaguchi, Satoshi; Tanabe, Hiroshi; Takano, Masashi; Horie, Kouji; Takei, Yuji; Imai, Yuichi; Hibino, Yumi; Hasegawa, Kosei; Takekuma, Munetaka; Nakamura, Kazuto; Takano, Hirokuni; Fujiwara, Keiichi; Masuyama, Hisashi

doi:10.1007/s10147-024-02585-1

Permalink : https://ousar.lib.okayama-u.ac.jp/67508

ID	67508
フルテキストURL	fulltext.pdf 492 KB
著者	Nagao, Shoji Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Nishio, Shin Department of Obstetrics and Gynecology, Kurume University School of Medicine Takehara, Kazuhiro Department of Gynecologic Oncology, NHO Shikoku Cancer Center Sato, Shinya Department of Obstetrics and Gynecology, Tottori University Satoh, Toyomi Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba Shimada, Muneaki Department of Gynecology, Tohoku University Hospital Yamaguchi, Satoshi Department of Medical Oncology, Hyogo Cancer Center Tanabe, Hiroshi Department of Obstetrics and Gynecology, Jikei University School of Medicine Takano, Masashi Department of Obstetrics and Gynecology, National Defense Medical College Horie, Kouji Department of Gynecologic Oncology, Saitama Cancer Center Takei, Yuji Department of Obstetrics and Gynecology, Jichi Medical University Imai, Yuichi Department of Obstetrics and Gynecology, Yokohama City University Hospital Hibino, Yumi Department of Gynecologic Oncology, NHO Shikoku Cancer Center Hasegawa, Kosei Department of Gynecologic Oncology, Saitama Medical University International Medical Center Takekuma, Munetaka Department of Gynecology, Shizuoka Cancer Center Nakamura, Kazuto Department of Gynecology, Gunma Prefectural Cancer Center Takano, Hirokuni Department of Obstetrics and Gynecology, Jikei University School of Medicine Fujiwara, Keiichi Department of Gynecologic Oncology, Saitama Medical University International Medical Center Masuyama, Hisashi Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID publons researchmap
抄録	Background We previously demonstrated the applicability of the concept of “platinum sensitivity” in recurrent endometrial cancer. Although immune checkpoint inhibitors have been widely incorporated into endometrial cancer treatment, the debate continues regarding treatment options in patients with recurrent endometrial cancer who have previously received platinum-based chemotherapy. In this study, we assessed the duration of response to secondary platinum-based treatment using pooled data from the SGSG-012/GOTIC-004/Intergroup study. Methods Among the 279 participants in the SGSG-012/GOTIC-004/Intergroup study wherein platinum-based chemotherapy was re-administered for managing recurrent endometrial cancer between January 2005 and December 2009, 130 (47%) responded to chemotherapy. We compared the relationship between platinum-free interval and duration of secondary platinum-based treatment using pooled data. Results In 40 patients (31%), the duration of response to secondary platinum-based treatment exceeded the platinum-free interval. The duration of response to secondary platinum-based treatment exceeded 12 months in 51 patients (39%) [platinum-free interval: < 12 months, 14/48 (29%); 12–23 months, 18/43 (42%); 24–35 months, 8/19 (42%); ≥ 36 months, 11/20 (55%)]. In particular, in eight patients (6%), the duration of response to secondary platinum-based treatment exceeded 36 months [platinum-free interval: < 12 months, 3/48 (6%); 12–23 months, 0/19 (0%); 24–35 months, 2/19 (11%); ≥ 36 months, 3/20 (15%)]. Conclusions Re-administration of platinum-based chemotherapy for recurrent endometrial cancer may result in a long-term response exceeding the platinum-free interval in some patients. Even in the current situation, where immune checkpoint inhibitors have been introduced, re-administration of platinum-based chemotherapy is worth considering.
キーワード	Recurrent endometrial cancer Re-administration of platinum-based chemotherapy Platinum-free interval Secondary platinum response
備考	The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: http://dx.doi.org/10.1007/s10147-024-02585-1
発行日	2024-07-13
出版物タイトル	International Journal of Clinical Oncology
巻	29巻
号	10号
出版者	Springer Science and Business Media LLC
開始ページ	1594
終了ページ	1601
ISSN	1341-9625
NCID	AA11086579
資料タイプ	学術雑誌論文
言語	英語
OAI-PMH Set	岡山大学
著作権者	© The Author(s) 2024
論文のバージョン	publisher
PubMed ID	39001945
DOI	10.1007/s10147-024-02585-1
Web of Science KeyUT	001272243200001
関連URL	isVersionOf https://doi.org/10.1007/s10147-024-02585-1
ライセンス	http://creativecommons.org/licenses/by/4.0/
Citation	Nagao, S., Nishio, S., Takehara, K. et al. Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study. Int J Clin Oncol 29, 1594–1601 (2024). https://doi.org/10.1007/s10147-024-02585-1
助成機関名	Okayama University Sankai Gynecologic Study Group